1488 related articles for article (PubMed ID: 18226324)
21. Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.
Polyzos SA; Anastasilakis AD; Makras P; Terpos E
Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):519-24. PubMed ID: 21811962
[TBL] [Abstract][Full Text] [Related]
22. Paget's disease of bone: experience from a centre in southern India.
Anjali ; Thomas N; Rajaratnam S; Shanthly N; Oommen R; Seshadri MS
J Assoc Physicians India; 2006 Jul; 54():525-9. PubMed ID: 17089899
[TBL] [Abstract][Full Text] [Related]
23. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
Whitson HE; Lobaugh B; Lyles KW
Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
[TBL] [Abstract][Full Text] [Related]
24. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
[TBL] [Abstract][Full Text] [Related]
26. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
Chakravarty K; Merry P; Scott DG
J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
[TBL] [Abstract][Full Text] [Related]
27. [Optimizing therapy in Paget disease].
Füessl HS
MMW Fortschr Med; 2005 Dec; 147(51-52):32. PubMed ID: 16402704
[No Abstract] [Full Text] [Related]
28. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
Cremers SC; Eekhoff ME; Den Hartigh J; Hamdy NA; Vermeij P; Papapoulos SE
J Bone Miner Res; 2003 May; 18(5):868-75. PubMed ID: 12733726
[TBL] [Abstract][Full Text] [Related]
29. Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid.
Devogelaer JP; Geusens P; Daci E; Gielen E; Denhaerynck K; Macdonald K; Hermans C; Vancayzeele S; Abraham I; Boonen S
Calcif Tissue Int; 2014 Mar; 94(3):311-8. PubMed ID: 24271562
[TBL] [Abstract][Full Text] [Related]
30. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
31. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
32. Pharmacotherapy of Paget's disease of bone.
Reid IR
Expert Opin Pharmacother; 2012 Apr; 13(5):637-46. PubMed ID: 22339140
[TBL] [Abstract][Full Text] [Related]
33. Paget disease of bone: therapeutic options.
Silverman SL
J Clin Rheumatol; 2008 Oct; 14(5):299-305. PubMed ID: 18838910
[TBL] [Abstract][Full Text] [Related]
34. The use of zoledronic acid for Paget's disease of bone.
Maricic M
Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
O'Doherty DP; Bickerstaff DR; McCloskey EV; Hamdy NA; Beneton MN; Harris S; Mian M; Kanis JA
J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
[TBL] [Abstract][Full Text] [Related]
36. Paget's disease and bisphosphonate-associated osteonecrosis of the jaws.
Gueiros LA; Lopes MA; Leão JC
J Oral Maxillofac Surg; 2008 Jun; 66(6):1319. PubMed ID: 18486809
[No Abstract] [Full Text] [Related]
37. [Therapy of Paget's disease].
Kurth AA
Orthopade; 2007 Feb; 36(2):118, 120-3. PubMed ID: 17252256
[TBL] [Abstract][Full Text] [Related]
38. [Intravenous bisphosphonates for bone Paget's disease: higher risk of adverse events].
Grados D; Martínez-Morillo M; Holgado S; Erra A
Med Clin (Barc); 2014 May; 142(10):469-70. PubMed ID: 24120108
[No Abstract] [Full Text] [Related]
39. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.
Harinck HI; Bijvoet OL; Blanksma HJ; Dahlinghaus-Nienhuys PJ
Clin Orthop Relat Res; 1987 Apr; (217):79-98. PubMed ID: 2951049
[TBL] [Abstract][Full Text] [Related]
40. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]